These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

234 related items for PubMed ID: 19379636

  • 1. Cardiac dysfunction induced by novel targeted anticancer therapy: an emerging issue.
    Chen MH.
    Curr Cardiol Rep; 2009 May; 11(3):167-74. PubMed ID: 19379636
    [Abstract] [Full Text] [Related]

  • 2. [Cutaneous side effects of the multikinase inhibitors sorafenib and sunitinib].
    Wollenberg A, Staehler M, Eames T.
    Hautarzt; 2010 Aug; 61(8):662-7. PubMed ID: 20631979
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues.
    Zambelli A, Della Porta MG, Eleuteri E, De Giuli L, Catalano O, Tondini C, Riccardi A.
    Breast; 2011 Apr; 20(2):176-83. PubMed ID: 21146409
    [Abstract] [Full Text] [Related]

  • 6. Response to sorafenib after sunitinib-induced acute heart failure in a patient with metastatic renal cell carcinoma: case report and review of the literature.
    Wong MK, Jarkowski A.
    Pharmacotherapy; 2009 Apr; 29(4):473-8. PubMed ID: 19323623
    [Abstract] [Full Text] [Related]

  • 7. Renal toxicity of targeted therapies.
    Kelly RJ, Billemont B, Rixe O.
    Target Oncol; 2009 Apr; 4(2):121-33. PubMed ID: 19421832
    [Abstract] [Full Text] [Related]

  • 8. Adverse effects of anticancer agents that target the VEGF pathway.
    Chen HX, Cleck JN.
    Nat Rev Clin Oncol; 2009 Aug; 6(8):465-77. PubMed ID: 19581909
    [Abstract] [Full Text] [Related]

  • 9. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice.
    Agostino NM, Chinchilli VM, Lynch CJ, Koszyk-Szewczyk A, Gingrich R, Sivik J, Drabick JJ.
    J Oncol Pharm Pract; 2011 Sep; 17(3):197-202. PubMed ID: 20685771
    [Abstract] [Full Text] [Related]

  • 10. Sorafenib and sunitinib.
    Kim A, Balis FM, Widemann BC.
    Oncologist; 2009 Aug; 14(8):800-5. PubMed ID: 19648603
    [No Abstract] [Full Text] [Related]

  • 11. Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib.
    McLellan B, Kerr H.
    Dermatol Ther; 2011 Aug; 24(4):396-400. PubMed ID: 21910797
    [Abstract] [Full Text] [Related]

  • 12. Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma.
    Hiles JJ, Kolesar JM.
    Am J Health Syst Pharm; 2008 Jan 15; 65(2):123-31. PubMed ID: 18192256
    [Abstract] [Full Text] [Related]

  • 13. [Medical treatment of metastatic renal cell carcinoma after the approval and market entry of multitargeted tyrosine kinase inhibitors in Germany].
    Bolenz C, Trojan L, Honeck P, Schöppler G, Herrmann E, Alken P, Michel MS, Häcker A.
    Aktuelle Urol; 2009 Jan 15; 40(1):31-6. PubMed ID: 19177319
    [Abstract] [Full Text] [Related]

  • 14. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
    La Vine DB, Coleman TA, Davis CH, Carbonell CE, Davis WB.
    Am J Clin Oncol; 2010 Jun 15; 33(3):217-20. PubMed ID: 19745694
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib.
    Patel TV, Morgan JA, Demetri GD, George S, Maki RG, Quigley M, Humphreys BD.
    J Natl Cancer Inst; 2008 Feb 20; 100(4):282-4. PubMed ID: 18270341
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.